Prognostic values of human epididymis protein 4 expression in patients with endometrial cancer: A systematic review and meta-analysis

被引:9
作者
Han, Li-na [1 ,2 ]
Han, Yi-wei [1 ,2 ]
Yan, Ping [1 ]
机构
[1] Hebei Gen Hosp, Dept Obstet & Gynecol, 348 Heping West Rd, Shijiazhuang 050051, Hebei, Peoples R China
[2] Hebei Med Univ, Grad Sch, Shijiazhuang, Hebei, Peoples R China
关键词
endometrial cancer; human epididymis protein 4; meta-analysis; prognosis; survival; SERUM HE-4; UTILITY; CA125; DIAGNOSIS; MARKER; METASTASIS; CARCINOMA; SURVIVAL;
D O I
10.1111/jog.15356
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background There is no consensus on the correlation between human epididymis protein 4 (HE4) and prognosis of endometrial cancer (EC). Therefore, we performed a meta-analysis to assess the relationship between HE4 and prognosis of EC. Methods In this systematic review and meta-analysis, the databases were searched. Correlation of serum or tissue HE4 with clinicopathological characteristics was determined by odds ratio (OR) or standardized mean difference (SMD) with 95% confidence interval (CI), respectively. The hazard ratio (HR) with 95% CI was calculated to evaluate the correlation between HE4 and survival outcome. Results A total of 38 published studies were eligible. We found that high levels of serum HE4 were associated with FIGO III-IV stage (SMD = 1.58, 95%CI: 1.18-1.98, p < 0.001), grade 3 (SMD = 0.66, 95%CI: 0.39-0.93, p = 0.001), >= 50% myometrial invasion (SMD = 0.78, 95%CI: 0.58-0.99, p < 0.001), lymphovascular space invasion (SMD = 0.82, 95%CI: 0.54-1.11, p = 0.001), lymph node metastasis (SMD = 1.27, 95%CI: 0.84-1.69, p < 0.001), cervical involvement (SMD = 0.71, 95%CI: 0.43-0.98, p = 0.003), parametrial involvement (SMD = 1.03, 95%CI: 0.71-1.35, p < 0.001) and peritoneal cytology (SMD = 0.49, 95%CI: 0.22-0.75, p < 0.001). High expression of tissue HE4 was only significantly associated with lymph node metastasis (OR = 6.19, 95%CI: 2.07-18.50, p = 0.001). High levels of serum HE4 were significantly associated with poor overall survival (univariate: HR = 3.77, 95%CI: 1.94-7.32, p < 0.001; multivariate: HR = 2.15, 95%CI: 1.65-2.80, p < 0.001) and disease-free survival (univariate: HR = 2.89, 95%CI: 2.14-3.88, p < 0.001; multivariate: HR = 2.31, 95%CI:1.20-2.67, p < 0.001) in EC. Compared with cancer antigen 125, serum HE4 may be a better prognostic indicator for EC. Conclusions High HE4 expression is associated with poor prognosis of EC and may be a potential prognostic biomarker for EC.
引用
收藏
页码:2255 / 2269
页数:15
相关论文
共 47 条
[1]  
Abbink K, 2018, TUMOR BIOL, V40, p101042831875710, DOI [10.1177/1010428318757103, 10.1177/1010428318757103, DOI 10.1177/1010428318757103]
[2]   The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program [J].
Angioli, Roberto ;
Capriglione, Stella ;
Scaletta, Giuseppe ;
Aloisi, Alessia ;
Miranda, Andrea ;
Nardone, Carlo De Cicco ;
Terranova, Corrado ;
Plotti, Francesco .
TUMOR BIOLOGY, 2016, 37 (04) :4973-4978
[3]   HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET) [J].
Antonsen, Sofie L. ;
Hogdall, Estrid ;
Christensen, Ib J. ;
Lydolph, Magnus ;
Tabor, Ann ;
Jakobsen, Annika Loft ;
Fago-Olsen, Carsten L. ;
Andersen, Erik S. ;
Jochumsen, Kirsten ;
Hogdall, Claus .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2013, 92 (11) :1313-1322
[4]   The Clinical Significance of DJ1 and L1CAM Serum Level Monitoring in Patients with Endometrial Cancer [J].
Bednarikova, Marketa ;
Vinklerova, Petra ;
Gottwaldova, Jana ;
Ovesna, Petra ;
Hausnerova, Jitka ;
Minar, Lubos ;
Felsinger, Michal ;
Valik, Dalibor ;
Cermakova, Zdenka ;
Weinberger, Vit .
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (12)
[5]   Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients [J].
Bignotti, E. ;
Ragnoli, M. ;
Zanotti, L. ;
Calza, S. ;
Falchetti, M. ;
Lonardi, S. ;
Bergamelli, S. ;
Bandiera, E. ;
Tassi, R. A. ;
Romani, C. ;
Todeschini, P. ;
Odicino, F. E. ;
Facchetti, F. ;
Pecorelli, S. ;
Ravaggi, A. .
BRITISH JOURNAL OF CANCER, 2011, 104 (09) :1418-1425
[6]   Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance [J].
Brennan, Donal J. ;
Hackethal, Andreas ;
Mann, Kristy P. ;
Mutz-Dehbalaie, Irene ;
Fiegl, Heidi ;
Marth, Christian ;
Obermair, Andreas .
BMC CANCER, 2015, 15
[7]   Serum HE4 as a prognostic marker in endometrial cancer - A population based study [J].
Brennan, Donal. J. ;
Hackethal, Andreas ;
Metcalf, Alex M. ;
Coward, Jermaine ;
Ferguson, Kaltin ;
Oehler, Martin K. ;
Quinn, Michael A. ;
Janda, Monika ;
Leung, Yee ;
Freemantle, Michael ;
Webb, Penelope M. ;
Spurdle, Amanda B. ;
Obermair, Andreas .
GYNECOLOGIC ONCOLOGY, 2014, 132 (01) :159-165
[8]   Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study [J].
Capriglione, Stella ;
Plotti, Francesco ;
Miranda, Andrea ;
Ricciardi, Roberto ;
Scaletta, Giuseppe ;
Aloisi, Alessia ;
Guzzo, Federica ;
Montera, Roberto ;
Angioli, Roberto .
TUMOR BIOLOGY, 2015, 36 (06) :4151-4156
[9]   ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up [J].
Colombo, N. ;
Creutzberg, C. ;
Amant, F. ;
Bosse, T. ;
Gonzalez-Martin, A. ;
Ledermann, J. ;
Marth, C. ;
Nout, R. ;
Querleu, D. ;
Mirza, M. R. ;
Sessa, C. .
ANNALS OF ONCOLOGY, 2016, 27 (01) :16-41
[10]   Survival after relapse in patients with endometrial cancer:: results from a randomized trial [J].
Creutzberg, CL ;
van Putten, WLJ ;
Koper, PC ;
Lybeert, MLM ;
Jobsen, JJ ;
Wárlám-Rodenhuis, CC ;
De Winter, KAJ ;
Lutgens, LCHW ;
van den Bergh, ACM ;
van der Steen-Banasik, E ;
Beerman, H ;
van Lent, M .
GYNECOLOGIC ONCOLOGY, 2003, 89 (02) :201-209